You are viewing: North America Theranostics Market analysis
Part of: Theranostics Market (Global)

The North America Theranostics Market was valued at $1195.5 Million in 2023 and projected to reach to $2462.8 Million by 2028, representing a compound annual growth rate of CAGR 15.6%. North America's theranostics market is poised for sustained expansion through 2028, driven by increasing demand for personalized medicine and companion diagnostics.

North America Theranostics Market (2023-2028) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

North America Theranostics Market Trends and Insights

  • North America's advanced healthcare infrastructure, high adoption of precision medicine, and significant investment in diagnostic and therapeutic technologies are driving this robust expansion.
  • The region benefits from strong regulatory frameworks, established reimbursement pathways, and a concentration of leading pharmaceutical and diagnostic companies. North America's theranostics market growth is fueled by increasing prevalence of chronic diseases, rising demand for personalized treatment approaches, and technological innovations in imaging and molecular diagnostics.
  • The region's healthcare systems prioritize early disease detection and targeted therapies, creating favorable conditions for theranostics adoption.
  • North America's competitive landscape includes major players investing heavily in research and development to advance theranostics platforms and expand clinical applications across oncology, cardiology, and neurology..

Key Market Statistics

  • CAGR (2023-2028) CAGR 15.6%
  • Market Size, 2023 ~USD 1195.5 Million
  • Forecast, 2028 ~USD 2462.8 Million
  • Geography North America

North America Theranostics Market Overview

Market Valuation & Growth :

North America's theranostics market reached $1,195.5 million in 2023 and is projected to grow to $2,462.8 million by 2028, driven by a robust 15.6% CAGR, outpacing the global average of 15.5%.

Advanced Healthcare Infrastructure :

The region's sophisticated healthcare systems, cutting-edge medical facilities, and strong regulatory frameworks create an ideal environment for theranostic innovation and rapid market adoption.

Precision Medicine Leadership :

North America leads in precision medicine adoption, with healthcare providers increasingly integrating diagnostic and therapeutic solutions to deliver personalized treatment strategies and improved patient outcomes.

Investment & R&D Momentum :

Significant capital investment in diagnostic and therapeutic technologies, coupled with strong pharmaceutical and biotech R&D spending, accelerates theranostic development and commercialization across the region.

North America Theranostics Market Dynamics

  • Healthcare providers are investing heavily in integrated diagnostic-therapeutic platforms to improve treatment efficacy and reduce adverse outcomes.
  • The region's mature healthcare ecosystem, combined with favorable reimbursement policies and strong clinical adoption, supports continued market growth. Key growth catalysts include rising cancer incidence, expanding applications beyond oncology, and technological advancements in molecular imaging and targeted therapies.
  • Strategic partnerships between diagnostic companies and pharmaceutical manufacturers are accelerating product development.
  • Additionally, growing patient awareness and physician preference for precision-based treatment approaches will further propel market expansion through the forecast period..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • Merck KGaA
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • North America's theranostics market is projected to more than double from $1,195.5 million in 2023 to $2,462.8 million by 2028.
    • North America maintains a 15.6% CAGR, driven by precision medicine adoption and advanced healthcare infrastructure.
    • North America's strong regulatory environment and reimbursement policies accelerate theranostics commercialization and clinical integration.
    • North America leads in theranostics innovation with major investments from pharmaceutical and diagnostic companies in oncology and molecular imaging applications.

    Theranostics Market Report Scope

    Report Metric Details
    Base Year 2023
    Fastest Growing Segment THERANOSTICS CENTERS (End User)
    Forecast Period 2023-2028
    Growth Rate CAGR of 15.5% from 2023 to 2028
    Largest Segment RADIOPHARMACEUTICALS (Product)
    Market Size Base Year (Billions) ~USD 2.09 (2023)
    Revenue Forecast (Billions) ~USD 4.3 (2028)
    Segments Covered Product, Type, Application, End User

    North America Theranostics Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Product

    • Diagnostic Imaging
    • Ivd/Biomarker Screening
    • Radiopharmaceuticals
    • Software & Services

    By Type

    • Iodine-131
    • Lutetium-177
    • Other Radiopharmaceuticals
    • Radium-223
    • Samarium-153
    • Yttrium-90

    By Application

    • Bone Metastasis
    • Other Applications
    • Other Cancer
    • Other Cancers
    • Prostate Cancer

    By End User

    • Hospitals And Cancer Care Centers
    • Research And Academic Centers
    • Theranostics Centers

    Target Audience

    • Pharmaceutical & Biotech Companies : Develop targeted commercialization strategies for theranostic products in North America's high-value market, optimize pricing and reimbursement approaches, and identify partnership opportunities.
    • Diagnostic & Medical Device Manufacturers : Understand market demand for companion diagnostics and integrated diagnostic-therapeutic platforms, benchmark competitive positioning, and plan product launches in North America.
    • Healthcare Providers & Hospital Systems : Evaluate theranostic adoption trends, assess clinical and economic benefits, and make informed procurement decisions to enhance precision medicine capabilities and patient outcomes.
    • Investment & Private Equity Firms : Identify high-growth theranostics companies and market segments in North America, assess investment opportunities, and evaluate acquisition targets in this expanding precision medicine sector.
    • Regulatory & Policy Advisors : Monitor North America regulatory landscape, reimbursement policies, and healthcare trends shaping theranostics market dynamics to inform strategic guidance and compliance strategies.

    North America vs. other regions

    HowNorth America compares to the other 3 regional blocs covered in this market.

    Europe
    ~USD 698 Million · 19.4% wtd CAGR ·
    Asia Pacific
    ~USD 1077.5 Million · 13.8% wtd CAGR ·

    Countries within North America - compare and drill down

    Country2025 size (native)
    USUSD 2319.1 Million
    CanadaUSD 143.7 Million

    Country market size visualization

    US
    USD 2319.1 Million
    Canada
    USD 143.7 Million

    Reasons to Buy this Report

    • Regional Market Sizing & Forecasts : Obtain precise market valuations for North America ($1,195.5M in 2023) with detailed 5-year forecasts, enabling accurate business planning and investment decisions specific to this high-growth region.
    • Competitive Landscape Analysis : Understand key players, market consolidation trends, and competitive positioning within North America's theranostics ecosystem to identify partnership and acquisition opportunities.
    • Country-Level Insights : Access granular market data for US ($2,319.1M) and Canada ($143.7M), allowing targeted go-to-market strategies and resource allocation across North American markets.
    • Growth Driver Identification : Identify region-specific growth catalysts including regulatory approvals, reimbursement trends, and clinical adoption patterns driving the 15.6% CAGR in North America.
    • Strategic Investment Guidance : Make informed investment and expansion decisions with comprehensive North America market intelligence, including emerging opportunities in precision oncology and multi-indication theranostics.

    Frequently asked questions

    What is the current size of the North America theranostics market?

    The North America theranostics market was valued at $1,195.5 million in 2023 and is expected to reach $2,462.8 million by 2028.

    What is the projected growth rate for North America's theranostics market?

    North America's theranostics market is expected to grow at a compound annual growth rate (CAGR) of 15.6% from 2023 to 2028.

    What factors are driving growth in North America's theranostics market?

    Key drivers include advanced healthcare infrastructure, high adoption of precision medicine, increasing chronic disease prevalence, technological innovations in diagnostics, and strong regulatory and reimbursement frameworks in North America.

    Which therapeutic areas are leading North America's theranostics market expansion?

    Oncology, cardiology, and neurology are the primary therapeutic areas driving North America's theranostics market growth, supported by significant clinical applications and research investments.

    How does North America's theranostics market compare to global trends?

    North America's 15.6% CAGR slightly exceeds the global average of 15.5%, reflecting the region's leadership in precision medicine adoption and healthcare innovation.

    RESEARCH METHODOLOGY

    The study involved four major activities in estimating the current size of the theranostics market. Exhaustive secondary research was done to collect information on the market, peer, and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

    Secondary Research

    The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial theranostics market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as OEMs, CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the theranostics market. The primary sources from the demand side include medical CDMOs, oncologists, doctors, radiologists, technicians, and service providers. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

    A breakdown of the primary respondents is provided below:

    Theranostics Market Size, and Share

    *Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note: Companies are classified into tiers based on their total revenue. As of 2021, Tier 1 = >USD 1,000 million, Tier 2 = USD 500–1,000 million, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Estimation Methodology

    In this report, the theranostics market’s size was determined using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the market business were determined through various insigh ts gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

    Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:

    • Generating a list of major global players operating in the theranostics market.
    • Mapping annual revenues generated by major global players from the product segment (or nearest reported business unit/category)
    • Revenue mapping of major players to cover a major share of the global market share, as of 2022
    • Extrapolating the global value of the theranostics market industry

    Theranostics Market Size, and Share

    Data Triangulation

    After arriving at the overall market size from the market size estimation process explained above, the global theranostics market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the market was validated using top-down and bottom-up approaches.

    Market Definition

    Theranostics is a term used for diagnosis and therapy. Theranostics can be broadly defined as a combination of molecularly targeted imaging and therapy, whereas imaging helps to gain information regarding presence of targeted moleculaes on cell surface and therapy progression. Radiotheranostics involves the use of radionuclide/radiopharmaceutical that delivers targeted radiation to kill the cancerous cells and imaging modality such as positron emission tomography (PET) is used to locate the cancer.  FDA approved theranostics procedures are performed for different applications such as prostate cancer, neuroendocrine tumor, etc. These procedures are mainly performed in hospitals, cancer care centers, and  theranostics centers.

    Key Stakeholders

    • Senior Management
    • End Users
    • R&D Department
    • Finance/Procurement Department

    Objectives of the Study

    • To define, describe, and forecast the size of theranostics market based on product, application, end user, and region
    • To provide detailed information regarding the major factors influencing the growth potential of the global market (drivers, restraints, opportunities, challenges, and trends)  
    • To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global market.   
    • To analyze key growth opportunities in the global market for key stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of market segments and/or subsegments with respect to three major regions, namely, North America (US and Canada), Europe (Germany, France, the UK, and the RoE), Asia Pacific (Japan, China, India, and the RoAPAC), and Rest of the World (Latin America and Middle East and Africa).
    • To profile the key players in the market and comprehensively analyze their market shares and core competencies.
    • To track and analyze the competitive developments undertaken in the global market, such as product launches; agreements; expansions; and mergers & acquisitions.

    Available Customizations

    With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the present global theranostics market report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of the top fifteen companies

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

    Geographic Analysis

    • Further breakdown of the Rest of Europe theranostics market into Italy, Spain Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among others
    • Further breakdown of the Rest of Asia Pacific theranostics market into Australia, South Korea, Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries

    Get the Full Theranostics Market Report

    Full forecast, segment splits, and company analysis for all Theranostics Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status